- Home
- CRTO vs COGT Comparison
CRTO vs COGT Comparison
Compare CRTO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- COGT
- Stock Information
- Founded
- CRTO 2005
- COGT 2014
- Country
- CRTO France
- COGT United States
- Employees
- CRTO N/A
- COGT N/A
- Industry
- CRTO Advertising
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- COGT Health Care
- Exchange
- CRTO Nasdaq
- COGT Nasdaq
- Market Cap
- CRTO 1.2B
- COGT 1.1B
- IPO Year
- CRTO 2013
- COGT 2018
- Fundamental
- Price
- CRTO $21.07
- COGT $15.52
- Analyst Decision
- CRTO Buy
- COGT Strong Buy
- Analyst Count
- CRTO 9
- COGT 11
- Target Price
- CRTO $39.11
- COGT $21.20
- AVG Volume (30 Days)
- CRTO 458.4K
- COGT 2.1M
- Earning Date
- CRTO 10-29-2025
- COGT 11-11-2025
- Dividend Yield
- CRTO N/A
- COGT N/A
- EPS Growth
- CRTO 44.35
- COGT N/A
- EPS
- CRTO 2.38
- COGT N/A
- Revenue
- CRTO $1,946,032,000.00
- COGT N/A
- Revenue This Year
- CRTO N/A
- COGT N/A
- Revenue Next Year
- CRTO $1.84
- COGT N/A
- P/E Ratio
- CRTO $9.00
- COGT N/A
- Revenue Growth
- CRTO N/A
- COGT N/A
- 52 Week Low
- CRTO $20.84
- COGT $3.72
- 52 Week High
- CRTO $47.27
- COGT $16.22
- Technical
- Relative Strength Index (RSI)
- CRTO 35.37
- COGT 71.71
- Support Level
- CRTO $21.30
- COGT $13.72
- Resistance Level
- CRTO $22.07
- COGT $16.22
- Average True Range (ATR)
- CRTO 0.67
- COGT 0.69
- MACD
- CRTO -0.07
- COGT 0.24
- Stochastic Oscillator
- CRTO 0.86
- COGT 85.02
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.